62 results about "Liver disorder" patented technology

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.

Provided are an inhibitor containing a bicyclic derivative, a preparation method therefor and the use thereof. In particular, involved are a compound shown by general formula (I), a preparation method therefor, a pharmaceutical composition thereof, and the use thereof as an RET inhibitor in the treatment of cancers, inflammations, chronic liver diseases, diabetes, cardiovascular diseases, AIDS, and other related diseases, wherein each substituent in general formula (I) has the same definition as that given in the description.

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

The application discloses a prognosis risk prediction model construction system and method based on chronic disease real world data, comprising a multi-source real world data acquisition and access module, a data standardization and quality control module, a multi-dimensional feature engineering and screening module, a comorbidity feature fusion and data set construction module, a prognosis risk prediction model training and optimization module, a model multi-dimensional verification and evaluation module, a model deployment and risk stratification output module; a special multi-source real world data acquisition and quality control system for chronic liver disease, diabetes and hypertension is constructed, data standardization processing is realized in combination with a chronic disease clinical diagnosis and treatment guideline, through multi-dimensional missing value, abnormal value processing and data deduplication integration, the quality and availability of the real world data are effectively improved, the core problem of disorderly and low-quality real world data in the prior art is solved, and a high-quality data source basis is provided for model construction.

The present disclosure is directed to a method of monitoring treatment of metabolic dysfunction-associated steatohepatitis (MASH) in a patient by initiating a treatment by administering Compound 1: (Compound 1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient, determining percentage increase in the level of SHBG from baseline, and continuing administration of Compound 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof to the patient if the percentage increase in the level of SHBG is at least 50% from baseline.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize treatment with a THR-β agonist.

The invention relates to the technical field of medical auxiliary instruments, and discloses an abdominal puncture auxiliary device for the hepatopathy department, the abdominal puncture auxiliary device comprises a supporting plate main body, the top of the supporting plate main body is slidably connected with a trunk fixing structure. According to the abdominal puncture auxiliary device for the hepatopathy department, a movable plate slidably connected to the top of the supporting plate body is matched with a limiting block and a threaded rod with a handle, so that a trunk is rapidly clamped by a first clamping plate, and the left-right position of the trunk is adjusted; a clamping block is driven by a buckle shell with a first spring and a pull rod to be connected with a plurality of clamping grooves in a supporting plate body in a clamped mode, accurate adjustment and locking of the overall position of the trunk fixing structure are achieved, and a multi-degree-of-freedom connecting rod mechanism is formed by sequentially hinging a first connecting rod, a second connecting rod and a third connecting rod and provided with a resistance pad at the hinged position; flexible hovering and positioning of the limbs of the patient are achieved, and automatic adaptation and elastic clamping of the upper limbs of the patient are achieved.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

To provide methods and systems for assays that accurately determine lipoproteins in a plasma or serum sample and predict patient mortality, in contrast to conventional lipid panels incapable of detecting the presence of LP-X or LP-Z.SOLUTION: Described herein are methods for the determination of patient mortality from alcoholic hepatitis in biosamples by NMR spectroscopy, and more specifically, methods for the determination of a Z index score based on lipoprotein constituent LP-Z in blood plasma and serum.SELECTED DRAWING: Figure 4

This document describes bile acid derivatives, their manufacturing methods, and their uses. These derivatives have shown potential as therapeutic agents for the treatment of liver diseases.

Disclosed herein are small molecule GIP / GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

Bile acid derivatives, methods of manufacture thereof, and uses thereof are disclosed herein. The bile acid derivatives have demonstrated potential as therapeutics for treating liver disease.

Disclosed are chimeric agonists of GCGR, GIPR, GLP-1R, and Y2R, and their use in the treatment of diseases and conditions such as diabetes, obesity, Alzheimer's disease, liver disease, substance addiction, traumatic brain injury, chronic kidney disease, inflammation and cardiovascular diseases.

The present invention relates to Bifidobacterium longum strain CECT 30763, to cellular components, metabolites and secreted molecules thereof, to compositions comprising the products mentioned above, and to their use in the prevention or treatment of mood disorders (e.g., depression and anxiety), cardiovascular metabolic disorders or liver disorders presented alone or as a co-disease.

Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver. Such liver disorders include fatty liver diseases are effective for reducing high levels of liver enzymes with a favorable safety profile. The methods and uses comprise administering to the subject an effective amount of a selective nonsteroidal glucocorticoid receptor modulator such as relacorilant, including methods and uses in combination with another drug, without adverse effects on liver enzyme levels, or on liver function. In embodiments, the other drug may be a drug that may cause liver toxicity, such as drugs that inhibit CYP3A enzymes, e.g., itraconazole or ketoconazole.

Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.

Provided herein are processes of producing volixibat and volixibat analogs, or their pharmaceutically acceptable salts, hydrates, or solvates thereof. Further provided herein are compounds of volixibat analogs, intermediates, or their pharmaceutically acceptable salts, hydrates, or solvates thereof. Additionally provided herein are crystalline forms of potassium volixibat salts. Provided herein are pharmaceutical compositions and dosage forms of the compositions comprising the compounds as described herein. Further provided herein are methods and kits of treating liver disease, hyperlipidemia, high cholesterol, arteriosclerosis, or Syndrome X using the compositions comprising the compounds as described herein.

Disclosed herein are formulations of small molecule GIP / GLP-1 dual receptor agonists and uses thereof.

The application discloses a kind of chronic disease auxiliary drug curative effect evaluation and personalized recommendation method, comprising the following steps: step one: real world data acquisition, step two: data standardization and annotation, step three: curative effect evaluation model construction, step four: patient population stratification, step five: personalized drug recommendation, step six: data update and model iteration;The application is aimed at the clinical characteristics of three kinds of chronic diseases, liver disease, diabetes and hypertension, and constructs a multidimensional real world database and a targeted curative effect evaluation model, realizes the personalized and accurate recommendation of the auxiliary drug of the three kinds of chronic diseases, breaks through the limitation of single disease drug recommendation, effectively improves the clinical curative effect of auxiliary drug, reduces the risk of adverse drug reactions, and provides scientific support for the clinical rational use of drugs for the three kinds of chronic diseases.

The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH).

The invention relates to a protein combination, a kit and a system for predicting secondary infection of a patient with hepatitis B related hepatic failure, and comprises application of the protein combination in preparation of a product for predicting secondary infection of the patient with hepatitis B related hepatic failure, and the combination comprises lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and dermatin DPT. The combination is used as a biomarker to directly reflect a core mechanism of inflammation-blood coagulation imbalance of secondary infection of the liver disease, has high specificity, is not interfered by the liver disease background, and can more truly reflect a potential reaction state of an organism to infection under the liver disease background, so that the problems of failure and false negative of a traditional index are solved; the composition can generate obvious concentration change at the early hospital admission stage of a patient when no clinical infection sign exists, and a key time window is provided for early preventive treatment.

Disclosed herein are inhibitors of aminocarboxymuconate semialdehyde decarboxylase (ACMSD), pharmaceutical compositions and methods for using these compounds to treat or prevent one or more ACMSD-related diseases such as, for example, muscle structure disorders, neuronal activation disorders, muscle fatigue disorders, muscle mass disorders, beta oxidation diseases, metabolic diseases, cancer, vascular diseases, ocular vascular diseases, muscular eye diseases, liver diseases, inflammatory diseases or renal diseases.

The disclosure relates to a composition comprising BRINP3 variants and methods of using the same for treatment of obesity, weight gain, diabetes, MASH, or MASLD in subjects in need thereof.